Which has preferable valuation & earnings, TRLV or LNTH?

Lantheus has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis N/A N/A N/A N/A N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.39

Does the media favor TRLV or LNTH?

In the previous week, Trulieve Cannabis had 1 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Trulieve Cannabis and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.44 beat Trulieve Cannabis' score of 0.32 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, BLTE or TRLV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Trulieve Cannabis N/A N/A N/A N/A N/A

Is BLTE or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Trulieve Cannabis N/A N/A N/A

Does the media refer more to BLTE or TRLV?

In the previous week, Belite Bio had 6 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Belite Bio and 6 mentions for Trulieve Cannabis. Belite Bio's average media sentiment score of 0.83 beat Trulieve Cannabis' score of 0.32 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, LQDA or TRLV?

Trulieve Cannabis has lower revenue, but higher earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 38.82 -$68.92M $1.37 50.12 Trulieve Cannabis N/A N/A N/A N/A N/A

Does the media refer more to LQDA or TRLV?

In the previous week, Liquidia had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 14 mentions for Liquidia and 6 mentions for Trulieve Cannabis. Liquidia's average media sentiment score of 0.64 beat Trulieve Cannabis' score of 0.32 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TRLV or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis N/A N/A N/A N/A N/A Amneal Pharmaceuticals $3.02B 1.84 $72.06M $0.49 35.59

Does the media prefer TRLV or AMRX?

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Amneal Pharmaceuticals and 6 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.99 beat Trulieve Cannabis' score of 0.32 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, TRLV or DFTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis N/A N/A N/A N/A N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is TRLV or DFTX more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Definium Therapeutics N/A -84.01% -63.66%

Does the media refer more to TRLV or DFTX?

In the previous week, Definium Therapeutics had 4 more articles in the media than Trulieve Cannabis. MarketBeat recorded 10 mentions for Definium Therapeutics and 6 mentions for Trulieve Cannabis. Definium Therapeutics' average media sentiment score of 0.78 beat Trulieve Cannabis' score of 0.32 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trulieve Cannabis (TRLV) Competitors

$12.09 -0.02 (-0.17%)

As of 09/4/2026 03:58 PM Eastern

Compare

TRLV vs. LNTH, BLTE, LQDA, AMRX, and DFTX

Should you buy Trulieve Cannabis stock or one of its competitors? Trulieve Cannabis's main competitors and comparable companies include Lantheus (LNTH), Belite Bio (BLTE), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trulieve Cannabis compare to Lantheus?

Trulieve Cannabis (NYSE:TRLV) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

99.1% of Lantheus shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Trulieve Cannabis had 1 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Trulieve Cannabis and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.44 beat Trulieve Cannabis' score of 0.32 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis currently has a consensus price target of $15.00, suggesting a potential upside of 24.07%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.07%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Trulieve Cannabis' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Lantheus	17.69%	28.10%	14.35%

Lantheus has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39

Summary

Lantheus beats Trulieve Cannabis on 8 of the 11 factors compared between the two stocks.

How does Trulieve Cannabis compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Belite Bio presently has a consensus price target of $214.64, suggesting a potential upside of 10.86%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 24.07%. Given Trulieve Cannabis' higher probable upside, analysts plainly believe Trulieve Cannabis is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Belite Bio had 6 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Belite Bio and 6 mentions for Trulieve Cannabis. Belite Bio's average media sentiment score of 0.83 beat Trulieve Cannabis' score of 0.32 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis' return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Belite Bio beats Trulieve Cannabis on 7 of the 10 factors compared between the two stocks.

How does Trulieve Cannabis compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Trulieve Cannabis (NYSE:TRLV) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Liquidia has a net margin of 30.74% compared to Trulieve Cannabis' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Trulieve Cannabis	N/A	N/A	N/A

Trulieve Cannabis has lower revenue, but higher earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.82	-$68.92M	$1.37	50.12
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

In the previous week, Liquidia had 8 more articles in the media than Trulieve Cannabis. MarketBeat recorded 14 mentions for Liquidia and 6 mentions for Trulieve Cannabis. Liquidia's average media sentiment score of 0.64 beat Trulieve Cannabis' score of 0.32 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.5% of Liquidia shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liquidia currently has a consensus target price of $98.08, suggesting a potential upside of 42.85%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 24.07%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Liquidia beats Trulieve Cannabis on 12 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Trulieve Cannabis (NYSE:TRLV) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Amneal Pharmaceuticals and 6 mentions for Trulieve Cannabis. Amneal Pharmaceuticals' average media sentiment score of 0.99 beat Trulieve Cannabis' score of 0.32 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 24.07%. Amneal Pharmaceuticals has a consensus price target of $19.00, indicating a potential upside of 8.94%. Given Trulieve Cannabis' higher possible upside, equities research analysts clearly believe Trulieve Cannabis is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Trulieve Cannabis' net margin of 0.00%. Trulieve Cannabis' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.84	$72.06M	$0.49	35.59

Summary

Amneal Pharmaceuticals beats Trulieve Cannabis on 10 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Definium Therapeutics?

Trulieve Cannabis (NYSE:TRLV) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

27.9% of Definium Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Trulieve Cannabis' return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Definium Therapeutics	N/A	-84.01%	-63.66%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Trulieve Cannabis presently has a consensus target price of $15.00, indicating a potential upside of 24.07%. Definium Therapeutics has a consensus target price of $63.00, indicating a potential upside of 65.40%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 4 more articles in the media than Trulieve Cannabis. MarketBeat recorded 10 mentions for Definium Therapeutics and 6 mentions for Trulieve Cannabis. Definium Therapeutics' average media sentiment score of 0.78 beat Trulieve Cannabis' score of 0.32 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Definium Therapeutics beats Trulieve Cannabis on 7 of the 10 factors compared between the two stocks.

Get Trulieve Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRLV vs. The Competition

Export

Metric	Trulieve Cannabis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.33B	$12.19B	$7.21B	$23.59B
Dividend Yield	N/A	2.59%	2.54%	3.73%
P/E Ratio	N/A	792.20	273.82	29.33
Price / Sales	N/A	754.17	625.63	20.96
Price / Cash	N/A	15.18	28.92	19.95
Price / Book	N/A	11.04	10.94	4.83
Net Income	N/A	$2.83B	$3.49B	$1.07B
7 Day Performance	4.95%	4.40%	1.61%	0.43%
1 Month Performance	38.01%	6.85%	4.41%	-0.78%
1 Year Performance	N/A	9.97%	24.18%	12.82%

Trulieve Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRLV Trulieve Cannabis	3.5001 of 5 stars	$12.09 -0.2%	$15.00 +24.1%	N/A	$2.33B	N/A	N/A	5,000
LNTH Lantheus	3.7799 of 5 stars	$100.88 -0.1%	$108.11 +7.2%	+84.4%	$6.59B	$1.54B	24.37	1,193	Positive News
BLTE Belite Bio	2.3891 of 5 stars	$156.70 +0.6%	$205.80 +31.3%	+194.5%	$6.27B	N/A	N/A	10	Analyst Upgrade Gap Down
LQDA Liquidia	4.2724 of 5 stars	$66.91 -1.8%	$98.08 +46.6%	+138.0%	$6.10B	$450.91M	48.84	50	Trending News
AMRX Amneal Pharmaceuticals	3.7246 of 5 stars	$17.68 +1.2%	$19.00 +7.5%	+81.3%	$5.58B	$3.02B	36.08	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TRLV) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trulieve Cannabis (TRLV) Competitors

TRLV vs. LNTH, BLTE, LQDA, AMRX, and DFTX

How does Trulieve Cannabis compare to Lantheus?

Summary

How does Trulieve Cannabis compare to Belite Bio?

Summary

How does Trulieve Cannabis compare to Liquidia?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Summary

How does Trulieve Cannabis compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trulieve Cannabis (TRLV) Competitors

TRLV vs. LNTH, BLTE, LQDA, AMRX, and DFTX

How does Trulieve Cannabis compare to Lantheus?

Do insiders and institutionals believe in TRLV or LNTH?

Does the media favor TRLV or LNTH?

Do analysts rate TRLV or LNTH?

Is TRLV or LNTH more profitable?

Which has preferable valuation & earnings, TRLV or LNTH?

Summary

How does Trulieve Cannabis compare to Belite Bio?

Which has stronger valuation & earnings, BLTE or TRLV?

Do insiders & institutionals have more ownership in BLTE or TRLV?

Do analysts rate BLTE or TRLV?

Does the media refer more to BLTE or TRLV?

Is BLTE or TRLV more profitable?

Summary

How does Trulieve Cannabis compare to Liquidia?

Is LQDA or TRLV more profitable?

Which has better earnings and valuation, LQDA or TRLV?

Does the media refer more to LQDA or TRLV?

Do institutionals and insiders have more ownership in LQDA or TRLV?

Do analysts rate LQDA or TRLV?

Summary

How does Trulieve Cannabis compare to Amneal Pharmaceuticals?

Does the media prefer TRLV or AMRX?

Do analysts prefer TRLV or AMRX?

Do insiders & institutionals believe in TRLV or AMRX?

Is TRLV or AMRX more profitable?

Which has stronger earnings & valuation, TRLV or AMRX?

Summary

How does Trulieve Cannabis compare to Definium Therapeutics?

Do institutionals and insiders believe in TRLV or DFTX?

Is TRLV or DFTX more profitable?

Which has better valuation & earnings, TRLV or DFTX?

Do analysts prefer TRLV or DFTX?

Does the media refer more to TRLV or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools